Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 8/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2270371 | 0.76 | NR3C2 (0.46) | NR3C2NR3C1MDM2MDM4PSEN1 | |
| SCHEMBL18614966 | 0.76 | NR3C2 (0.46) | NR3C2NR3C1MDM2MDM4PSEN1 | |
| SCHEMBL30938843 | 0.76 | NR3C2 (0.53) | NR3C2NR3C1MDM2MDM4PSEN1 | |
| SCHEMBL30938844 | 0.76 | NR3C2 (0.53) | NR3C2NR3C1MDM2MDM4PSEN1 | |
| SCHEMBL4510815 | 0.74 | NR3C2 (0.54) | NR3C2NR3C1MDM2MDM4PSEN1 | |
| SCHEMBL195445 | 0.73 | CNR2 (0.41) | MAPT | |
| SCHEMBL11295277 | 0.72 | NR3C2 (0.52) | NR3C2NR3C1MDM2MDM4PSEN1 | |
| SCHEMBL30065589 | 0.72 | NR3C2 (0.52) | NR3C2NR3C1MDM2MDM4PSEN1 | |
| SCHEMBL11856362 | 0.70 | NOS2 (0.48) | NR3C2MDM2PSEN1PSEN2APH1B | |
| SCHEMBL10833536 | 0.69 | NPSR1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536710-B1 | PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-8486967-B2 | Heteroaryl substituted piperidines | HOFFMANN-LA ROCHE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2536710-A2 | PIPERIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011101304-A2 | PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | HOFFMANN-LA ROCHE, INC. | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | APP, HPGDS, PSEN1 | NR3C2 3129/4885NR3C1 3641/4885MDM2 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.